54.174.225.82
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Genetic and Congenital

FDA Approves First Therapy for Children with Neurofibromatosis Type 1

The U.S. Food and Drug Administration has approved selumetinib (Koselugo) for the treatment of pediatric patients, ≥2 years of age, with neurofibromatosis type 1 (NF1). This is the first drug approved by the FDA to treat NF1. NF1 is a genetic disorder of the nervous system that causes tumors to...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-